Abstract
Study objectives:
Recent treatment guidelines for chronic insomnia recommend pharmacological and non-pharmacological therapies. One of the contemporary drug options for insomnia includes dual orexin receptor antagonist (DORA), such as suvorexant and lemborexant. We conducted a systematic review and meta-analysis for the treatment of insomnia with suvorexant and lemborexant based on randomized, double-blind, placebo-controlled Trials.
Methods:
We conducted a comprehensive search on three databases (PubMed/Medline, Web of Science, and Cochrane Library) till August 14, 2021, without any restrictions to retrieve the relevant articles. The effect sizes were computed presenting the pooled mean difference or risk ratio along with 95% confidence interval of each outcome.
Results:
Our search showed eight articles (five for suvorexant and three for lemborexant). Results of diary measures, rating scales, polysomnography results, treatment discontinuation, and adverse events were measured. All efficacy outcome measures favorably and significantly differed in the suvorexant compared to placebo. Safety profile did not differ significantly except for somnolence, excessive daytime sleepiness/sedation, fatigue, back pain, dry mouth, and abnormal dreams. Important adverse events including hallucinations, suicidal ideation/behavior and motor vehicle accidents did not differ between suvorexant and placebo. All the efficacy outcomes significantly differed between lemborexant 5 and lemborexant 10 compared to placebo. Somnolence rate for lemborexant 5 and lemborexant 10 and nightmare for lemborexant 10 were significantly higher than placebo.
Conclusion:
The present meta-analysis reported that suvorexant and lemborexant are efficacious and safe agents for the patients with insomnia. Further data in patients with insomnia and various comorbid conditions are needed.
Introduction
Insomnia is a condition in which a person has difficulty falling asleep or staying asleep (1) with associated consequences like daytime fatigue and sleepiness (2–4). Insomnia is a major health challenge in the general population (5). Various studies around the world have reported that the insomnia was a high prevalent disease, affecting around 10–30% of the general population (1, 6, 7). Around 30–40% of adults in the US report insomnia symptoms at some point in a given year (8) and in China the prevalence of any type of insomnia symptoms was 22.1% (9). It is more common in the elderly, women, and people with medical and mental illness (6, 7, 10). There are three necessary diagnostic criteria for insomnia in clinical practice: complaint of trouble falling or staying asleep, adequate opportunity for sleep, and daytime dysfunction (11–14).
Recent treatment guidelines for chronic insomnia recommend pharmacological and non-pharmacological therapies (15). Current armamentarium of contemporary drug options for insomnia include gamma-aminobutyric acid type-A receptor agonists, non-benzodiazepine Z-drugs, sedative-hypnotic benzodiazepines, sedative antidepressants, melatonin receptor agonists, sedative antihistamines, and dual orexin receptor antagonists, such as suvorexant and lemborexant (15). The orexin/hypocretin system has been developed as a target for the treatment of insomnia (16). Orexins are neuropeptides that have a role in regulating the sleep-wake cycle by maintaining wakefulness (17).
Suvorexant is a dual orexin receptor antagonist that promotes sleep through selective antagonism of the endogenous oroxin-stimulating neuropeptides in the orexin receptors OX1R and OX2R (18, 19). Lemborexant is another dual orexin receptor antagonist and acts as a competitive antagonist in both orexin receptors, which can possibly stop the awakening by blocking binding of orexin (20).
Several meta-analyses reported the findings of clinical trials for the effectiveness of both suvorexant and lemborexant (21), suvorexant alone (22–26), and lemborexant alone (27, 28) in insomnia patients with different study population and results. We performed a meta-analysis among largest number of randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant in insomnia patients to explore the efficacy and safety profile in more detail as it may relate to use of these agents in mental health clinics.
Materials and methods
Study design
The reporting of the present meta-analysis is in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) protocols (29). The PICO (population, intervention, control, and outcomes) question was: Do suvorexant and lemborexant improve various relevant clinical efficacy and safety outcomes at various time points in patients with insomnia compared to placebo group? The outcomes of interest include diary measures, rating scales and adverse events.
Identification of articles
A comprehensive search was performed by in three databases of PubMed/Medline, Web of Science, and Cochrane Library until August 14, 2021, without any restrictions to retrieve the relevant articles. The search strategy was (“suvorexant” or “lemborexant”) and (“insomnia”) and (“random*” or “trial*”). Moreover, the citations of the retrieved articles linked to the subject were examined to ensure that no study was missed and then the titles and abstracts of the relevant articles were evaluated; subsequently, the full texts of the articles following the eligibility criteria were downloaded.
Inclusion and exclusion criteria
The inclusion criteria were: (1) published randomized, double-blind, placebo-controlled trials; (2) studies reporting outcomes of suvorexant or lemborexant compared to placebo in insomnia patients; (3) participants had age ≥ 18 years at the time of enrollment. We rejected the following study types: Meta-analyses, studies with incomplete data, studies without a placebo group, conference papers, reviews, case-reports, studies reporting the outcomes in healthy individuals, unpublished studies, book chapters, studies with duplicate data and comment.
Data abstraction
One author (MS) extracted the data of the articles included in the meta-analysis. The extracted data were: first author, publication year, phase of the trial, duration of treatment, participants age range, type of treatment, sample size based on each outcome, and mean difference (MD) or risk ratio (RR) of each outcome. Another author (HK) re-checked them. Disagreements between the two authors were resolved by third author (AS).
Statistical analysis
The effect sizes were computed using the Review Manager 5.3 (RevMan 5.3) presenting the MD or RR along with 95% confidence interval (CI) for each outcome. To estimate the pooled MD or RR significance, the Z-test was applied with a p-value (two-sided) less than 0.05 considered as significant. An I2 statistic (Pheterogeneity < 0.1 or I2 > 50%) showed a significant heterogeneity and random-effects model was performed (30), and if the heterogeneity was insignificant, a fixed-effect model was applied (31).
Results
Study selection
Among three databases, 235 articles were retrieved that after removing duplicates and irrelevant articles based on titles/abstracts, 53 full-text articles were assessed (Figure 1). Subsequently, 45 articles were excluded based on the reasons (12 reviews, eight meta-analyses, 11 reported in health cases without insomnia and any disease, two unpublished, two retrospectives, six with no report of any relevant data related to our meta-analysis, three with no placebo group, and one with duplicate data). Finally, eight articles were included in the meta-analysis that one article involved four independent studies (23, 32–38).
FIGURE 1
Characteristics of the studies
The meta-analysis included 11 studies based on eight articles (Table 1). All articles were registered in Clinical trials.gov, except for one (32). Six articles were phase 3 (32, 33, 35, 36, 38, 39), and two were phase 2 trials (34, 37). All participants in the studies were age 18 years or older. Five articles including eight studies reported suvorexant therapy (32–34, 36, 39). Three publications with three studies reported lemborexant therapy in insomnia patients (35, 37, 38).
TABLE 1
| References | https://clinicaltrials.gov/ identifier | Phase | Duration | Age range, years | Reported treatment |
| Herring et al. (34) | NCT00792298 | 2 | 1 month | 18–64 | Suvorexant |
| Michelson et al. (36) | NCT01021813 | 3 | 1 year | ≥18 | Suvorexant |
| Herring et al. (23)* | NCT01097616 and NCT01097629 | 3 | 3 months | <65 and ≥65 | Suvorexant |
| Fan et al. (32) | – | 3 | 6 months | 18–64 | Suvorexant |
| Murphy et al. (37) | NCT01995838 | 2 | 6 months | 19–80 | Lemborexant |
| Rosenberg et al. (38) | NCT02783729 | 3 | 1 month | 55–88 | Lemborexant |
| Herring et al. (33) | NCT02750306 | 3 | 1 month | 50–90 | Suvorexant |
| Kärppä et al. (35) | NCT02952820 | 3 | 6 months | ≥18 | Lemborexant |
Characteristics of articles included in the meta-analysis.
*This article included four independent studies.
Efficacy measures for suvorexant vs. placebo
Results of diary measures for suvorexant therapy
Six efficacy outcomes [subjective total sleep time (sTST), subjective time to sleep onset (sTSO), subjective wake after sleep onset (sWASO), subjective quality of sleep (sQUAL), subjective number of awakenings (sNAW), and subjective refreshed feeling on waking (sFRESH)] were measured in the individuals (Tables 2, 3) during week 1 and months 1 and 3. All outcomes significantly differed in the suvorexant compared with placebo, with the exception of sQUAL at month 3, sNAW at week 1, sNAW at month 1, and sNAW at month 3. Figure 2 shows efficacy outcome results for suvorexant vs. placebo for three times.
TABLE 2
| Diary measures | N | No. of cases (suvorexant/placebo) | WMD | 95% CI | P-value | I2, % |
| sTST at week 1 | 5 | 1,739/1,732 | 21.05 | 16.00, 26.10 | <0.00001 | 64 |
| sTST at month 1 | 6 | 1,719/1,724 | 21.39 | 18.17, 24.61 | <0.00001 | 0 |
| sTST at month 3 | 4 | 1,113/1,328 | 19.10 | 14.63, 23.56 | <0.00001 | 46 |
| sTSO at week 1 | 5 | 1,739/1,732 | –8.72 | −11.04, −6.39 | <0.00001 | 40 |
| sTSO at month 1 | 6 | 1,719/1,724 | –8.72 | −11.03, −6.41 | <0.00001 | 0 |
| sTSO at month 3 | 4 | 1,113/1,328 | –8.23 | −10.92, −5.55 | <0.00001 | 25 |
| sWASO at week 1 | 4 | 1,231/1,480 | –7.91 | −10.21, −5.60 | <0.00001 | 18 |
| sWASO at month 1 | 5 | 1,683/1,675 | –8.33 | −10.70, −5.96 | <0.00001 | 0 |
| sWASO at month 3 | 4 | 1,113/1,328 | –6.45 | −9.20, −3.70 | <0.00001 | 0 |
| sQUAL at week 1 | 4 | 1,231/1,480 | 0.11 | 0.05, 0.17 | 0.0004 | 38 |
| sQUAL at month 1 | 6 | 1,738/1,731 | 0.17 | 0.12, 0.22 | <0.00001 | 0 |
| sQUAL at month 3 | 4 | 1,113/1,328 | 0.02 | −0.12, 0.17 | 0.74 | 81 |
| sNAW at week 1 | 4 | 1,231/1,480 | 0.02 | −0.40, 0.09 | 0.52 | 0 |
| sNAW at month 1 | 5 | 1,683/1,675 | –0.01 | −0.07, 0.05 | 0.72 | 18 |
| sNAW at month 3 | 4 | 1,113/1,328 | 0.00 | −0.06, 0.06 | 1.00 | 0 |
| sFRESH at week 1 | 4 | 1,231/1,480 | 0.10 | 0.06, 0.14 | <0.00001 | 0 |
| sFRESH at month 1 | 5 | 1,638/1,675 | 0.23 | 0.17, 0.29 | <0.00001 | 34 |
| sFRESH at month 3 | 4 | 1,113/1,328 | 0.14 | 0.08, 0.21 | <0.0001 | 0 |
The mean changes of efficacy outcome (diary measures) results from baseline in suvorexant vs. placebo.
95% CI, 95% confidence interval; N, number of comparisons/studies; sFRESH, subjective refreshed feeling on waking (0–4 scale); sNAW, subjective number of awakenings; sQUAL, subjective quality of sleep (1–4 scale); sTSO, subjective time to sleep onset (minutes); sTST, subjective total sleep time (minutes); sWASO, subjective wake after sleep onset (minutes); WMD, weighted mean difference.
TABLE 3
| N | No. of cases (suvorexant/placebo) | WMD | 95% CI | P-value | I2, % | |
| Rating scale | ||||||
| ISI at month 1 | 6 | 1,726/1,715 | –1.50 | −1.78, −1.22 | <0.00001 | 26 |
| ISI at month 3 | 4 | 1,106/1,318 | –1.50 | −1.88, −1.11 | <0.00001 | 46 |
| CGI-S at week 2 | 4 | 1,173/1,408 | –0.38 | −0.45, −0.30 | <0.00001 | 0 |
| CGI-S at month 1 | 6 | 1,812/1,802 | –0.38 | −0.44, −0.31 | <0.00001 | 13 |
| CGI-S at month 3 | 4 | 1,106/1,318 | –0.38 | −0.53, −0.22 | <0.00001 | 76 |
| PGI-S at week 2 | 4 | 1,173/1,408 | –0.42 | −0.49, −0.35 | <0.00001 | 44 |
| PGI-S at month 1 | 5 | 1,670/1,659 | –0.40 | −0.50, −0.30 | <0.00001 | 65 |
| PGI-S at month 3 | 4 | 1,106/1,318 | –0.37 | −0.46, −0.29 | <0.00001 | 14 |
| CGI-I at week 2 | 4 | 1,173/1,408 | –0.40 | −0.48, −0.32 | <0.00001 | 22 |
| CGI-I at month 1 | 5 | 1,670/1,659 | –0.40 | −0.47, −0.33 | <0.00001 | 0 |
| CGI-I at month 3 | 4 | 1,106/1,318 | –0.45 | −0.53, −0.37 | <0.00001 | 0 |
| PGI-I at week 2 | 4 | 1,173/1,408 | –0.47 | −0.58, −0.35 | <0.00001 | 54 |
| PGI-I at month 1 | 5 | 1,670/1,659 | –0.48 | −0.56, −0.41 | <0.00001 | 0 |
| PGI-I at month 3 | 4 | 1,106/1,318 | –0.42 | −0.54, −0.29 | <0.00001 | 55 |
| Polysomnography | ||||||
| TST at month 1 | 2 | 199/193 | 29.47 | 14.13, 44.81 | 0.0002 | 0 |
| LPS at day 1 | 5 | 950/1,275 | –13.40 | −18.20, −8.59 | <0.00001 | 57 |
| LPS at month 1 | 6 | 1,046/1,345 | –11.07 | −13.88, −8.26 | <0.00001 | 0 |
| LPS at month 3 | 4 | 815/1,012 | –6.37 | −9.44, −3.31 | <0.0001 | 35 |
| WASO at day 1 | 4 | 916/1,140 | –37.63 | −41.04, −34.22 | <0.00001 | 23 |
| WASO at month 1 | 5 | 1,014/1,227 | –25.80 | −29.48, −22.12 | <0.00001 | 0 |
| WASO at month 3 | 4 | 815/1,006 | –24.97 | −31.26, −18.68 | <0.00001 | 60 |
| Response rate | ||||||
| ISI responders at month 3 | 4 | 1,067/1,276 | 1.31 | 1.20, 1.42 | <0.00001 | 0 |
Analysis of the mean changes of efficacy outcomes from rating scales and polysomnography from baseline in suvorexant vs. placebo.
95% CI, 95% confidence interval; CGI-I, clinical global impression-improvement scale (1–7 scale); CGI-S, clinical global impression-severity scale (1–7 scale); ISI, insomnia severity index (0–28 scale); TST, total sleep time (minutes); LPS, latency to onset of persistent sleep (minutes); PGI-I, patient global impression-improvement scale (1–7 scale); PGI-S, patient global impression-severity scale (0–5 scale); N, number of comparisons/studies; RR, risk ratio; WASO, wakefulness after persistent sleep onset (minutes); WMD, weighted mean difference. The percentage of patients who had a clinically meaningful improvement (responders), prospectively defined as ≥6-point improvement from baseline in ISI score (40).
FIGURE 2
Rating scales and polysomnography results for suvorexant therapy
The studies compared six rating scales [insomnia severity index (ISI), clinical global impression-severity scale (CGI-S), patient global impression-severity scale (PGI-S), clinical global impression-improvement scale (CGI-I), and patient global impression-improvement scale (PGI-I)], three outcomes from polysomnography [TST, latency to onset of persistent sleep (LPS), and WASO], and ISI responders. For the rating scales, ISI, CGI-S, PGI-S, CGI-I, and PGI-I for several time points were calculated. For polysomnography, TST at month 1 and LPS and WASO at day 1 and months 1 and 3 were calculated. ISI responders [the percentage of patients who had a clinically meaningful improvement (responders), prospectively defined as ≥ 6-point improvement from baseline in ISI score] were measured in month 3 (40). All outcomes from rating scales and polysomnography differed significantly between the two study groups.
Treatment discontinuation and adverse events for suvorexant therapy vs. placebo
The results of outcomes of treatment discontinuation and adverse events are shown in Table 4. The mean changes from baseline in weight and proportions of patients with ≥ 7% increase or decrease in weight (weight: ≥ 7%) has been calculated in two times intervals. Although discontinuation rates did not differ between the two study groups, several safety outcomes were significantly higher in suvorexant compared to placebo for at least one drug-related adverse event, somnolence, excessive daytime sleepiness/sedation, fatigue, abnormal dreams, back pain, and dry mouth.
TABLE 4
| Adverse events | N | No. of cases (suvorexant/placebo) | RR | 95% CI | P-value | I2, % |
| Discontinuation due to all cause* | 7 | 1,978/1,218 | 0.95 | 0.82, 1.10 | 0.48 | 0 |
| Discontinuation due to intolerability* | 7 | 1,978/1,218 | 1.00 | 0.74, 1.35 | 1.00 | 29 |
| Discontinuation due to inefficacy* | 7 | 1,978/1,218 | 0.75 | 0.52, 1.09 | 0.13 | 0 |
| ≥1 adverse event | 7 | 1,986/1,228 | 1.07 | 0.99, 1.15 | 0.07 | 0 |
| ≥1 drug-related adverse event** | 7 | 1,986/1,228 | 1.62 | 1.40, 1.89 | <0.00001 | 10 |
| ≥1 serious adverse event | 7 | 1,986/1,228 | 0.70 | 0.27, 1.84 | 0.47 | 52 |
| Discontinued owing to adverse event | 3 | 723/461 | 1.37 | 0.88, 2.13 | 0.16 | 0 |
| Somnolence | 7 | 1,986/1,228 | 3.26 | 2.29, 4.63 | <0.00001 | 0 |
| Excessive daytime sleepiness/sedation*** | 5 | 1,784/1,025 | 3.48 | 1.13, 10.67 | 0.03 | 0 |
| Fatigue | 6 | 1,844/1,085 | 2.09 | 1.28, 3.43 | 0.003 | 3 |
| Cataplexy | 6 | 1,926/1,168 | Not estimable | – | − | – |
| Sleep paralysis | 6 | 1,926/1,168 | 2.84 | 0.49, 16.35 | 0.24 | 0 |
| Complex sleep–related behaviors | 6 | 1,926/1,168 | 1.66 | 0.17, 15.84 | 0.66 | 0 |
| Hypnagogic/hypnopompic hallucination | 6 | 1,926/1,168 | 3.12 | 0.67, 14.47 | 0.15 | 0 |
| Abnormal dreams | 4 | 1,263/767 | 2.91 | 1.12, 7.60 | 0.03 | 0 |
| Suicidal ideation/behavior | 6 | 1,926/1,168 | 1.91 | 0.46, 7.92 | 0.38 | 20 |
| Events indicative of abuse potential**** | 6 | 1,926/1,168 | 1.08 | 0.69, 1.68 | 0.74 | 0 |
| Fall# | 6 | 1,926/1,168 | 1.03 | 0.56, 1.89 | 0.92 | 19 |
| Headache | 7 | 1,986/1,228 | 1.13 | 0.86, 1.47 | 0.39 | 0 |
| Dizziness | 6 | 1,844/1,685 | 1.62 | 0.57, 4.57 | 0.36 | 85 |
| Back pain | 5 | 1,784/1,025 | 0.51 | 0.27, 0.97 | 0.04 | 0 |
| Dry mouth | 7 | 1,986/1,228 | 2.15 | 1.23, 3.76 | 0.008 | 0 |
| Nasopharyngitis | 5 | 1,784/1,025 | 0.95 | 0.71, 1.28 | 0.75 | 0 |
| Motor vehicle accidents/violations## | 5 | 1,660/963 | 1.21 | 0.72, 2.05 | 0.47 | 11 |
| Sleep-onset paralysis | 2 | 663/401 | 1.49 | 0.06, 36.41 | 0.81 | – |
| Weight: ≥7% increase at month 3 | 4 | 1,250/1,514 | 1.38 | 0.78, 2.45 | 0.26 | 0 |
| Weight: ≥7% decrease at month 3 | 4 | 1,250/1,514 | 1.85 | 0.84, 4.11 | 0.13 | 0 |
Treatment discontinuation and individual adverse events for suvorexant vs. placebo.
95% CI, 95% confidence interval; N, number of comparisons/studies; RR, risk ratio; weight: ≥7%, the mean changes from baseline in weight and proportions of patients with ≥ 7% increase or decrease in weight.
*The counts for discontinuations due to adverse events are based on the period in which the adverse event started.
**Drug-related adverse event a determined by the investigator to be related to the drug (determination made while blinded).
***Excessive daytime sleepiness was defined as a more persistent daytime sleepiness than typical next-day residual somnolence.
****Terms included depersonalization, derealization, dissociation, euphoric mood, mania, hallucination, and potential study medication misuse.
#Falls were adjudicated to determine whether they were suggestive of cataplexy.
##Includes spontaneously reported events when the patient was the driver and events elicited via a motor vehicle accidents and violations questionnaire.
Efficacy measures for lemborexant vs. placebo
Diary measures results for lemborexant 5 therapy
Three outcomes [subjective sleep onset latency (sSOL), subjective sleep efficiency (sSE), and sWASO] were measured in the individuals with insomnia (Table 5) during first seven nights and month 1. All the outcomes significantly differed between the lemborexant 5 compared to placebo.
TABLE 5
| Diary measures | N | No. of cases (lemborexant 5/placebo) | WMD | 95% CI | P-value | I2, % |
| sSOL at first seven nights | 2 | 569/516 | –12.05 | −18.45, −5.55 | 0.0003 | 79 |
| sSOL at month 1 | 2 | 550/496 | –11.80 | −21.70, −1.90 | 0.02 | 88 |
| sSE at first seven nights | 2 | 624/511 | 4.10 | 2.88, 5.32 | <0.00001 | 0 |
| sSE at month 1 | 2 | 543/490 | 3.16 | 0.84, 5.49 | 0.008 | 52 |
| sWASO at first seven nights | 2 | 571/516 | –13.19 | −19.33, −7.26 | <0.0001 | 0 |
| sWASO at month 1 | 2 | 551/596 | –6.74 | −13.12, −0.37 | 0.04 | 0 |
The mean changes of efficacy outcome (diary measures) results from baseline in lemborexant 5 vs. placebo.
95% CI, 95% confidence interval; N, number of comparisons/studies; sSOL, subjective sleep onset latency (minutes); sSE, subjective sleep efficiency (percentage); sWASO, subjective wake after sleep onset (minutes); WMD, weighted mean difference.
Results of diary measures for lemborexant 10 therapy
The outcomes of sSOL, sSE, and sWASO were measured in the insomnia patients (Table 6) during first seven nights and month 1. All the outcomes showed significant difference between the lemborexant 10 compared to placebo.
TABLE 6
| Diary measures | N | No. of cases (lemborexant 10/placebo) | WMD | 95% CI | P-value | I2, % |
| sSOL at first seven nights | 2 | 576/516 | –12.45 | −16.94, −7.96 | <0.00001 | 60 |
| sSOL at month 1 | 2 | 555/496 | –13.11 | −19.37, −6.85 | <0.0001 | 71 |
| sSE at first seven nights | 2 | 564/511 | 6.32 | 4.99, 7.64 | <0.00001 | 3 |
| sSE at month 1 | 2 | 541/490 | 5.54 | 1.52, 9.56 | 0.007 | 81 |
| sWASO at first seven nights | 2 | 572/516 | –21.38 | −31.51, −11.25 | <0.0001 | 62 |
| sWASO at month 1 | 2 | 550/496 | –13.77 | −28.65, 1.11 | 0.07 | 75 |
The mean changes of efficacy outcome (diary measures) results from baseline in lemborexant 10 vs. placebo.
95% CI, 95% confidence interval; N, number of comparisons/studies; sSOL, subjective sleep onset latency (minutes); sSE, subjective sleep efficiency (percentage); sWASO, subjective wake after sleep onset (minutes); WMD, weighted mean difference.
Supplementary Table 1 shows the outcomes of sTST, sSE, and sWASO in the insomnia patients during first seven nights and month 1 comparing 5 and 10 mg doses of lemborexant. None of the outcomes differed significantly between the comparison groups, with the exceptions of sSE at First seven nights and sSE at month 1.
Treatment discontinuation and adverse events for leborexant therapy
Table 7 shows treatment discontinuation and individual adverse events for lemborexant 5 compared with placebo. There were only significant differences between two groups (lemborexant 5 and placebo) for any treatment-related treatment-emergent adverse event (TEAE) and somnolence.
TABLE 7
| Adverse events | N | No. of cases (lemborexant 5/placebo) | RR | 95% CI | P-value | I2, % |
| Discontinuation due to all cause | 2 | 589/534 | 1.02 | 0.76, 1.37 | 0.91 | 20 |
| Discontinuation due to intolerability | 2 | 589/534 | 1.06 | 0.45, 2.46 | 0.90 | 0 |
| Any TEAE | 3 | 618/584 | 1.01 | 0.90, 1.13 | 0.86 | 0 |
| Any treatment-related TEAE | 3 | 618/584 | 1.69 | 1.29, 2.22 | 0.0001 | 0 |
| Any severe TEAE | 2 | 580/528 | 1.05 | 0.50, 2.20 | 0.89 | 43 |
| Any serious TEAE | 3 | 618/584 | 1.46 | 0.55, 3.90 | 0.45 | 0 |
| Any TEAE leading to discontinuation of study drug | 3 | 618/584 | 1.05 | 0.51, 2.15 | 0.89 | 0 |
| Any TEAE leading to interruption of study drug | 2 | 580/528 | 1.73 | 0.74, 4.07 | 0.21 | 0 |
| Death | 2 | 580/528 | Not estimable | – | − | – |
| Somnolence | 3 | 618/584 | 4.05 | 2.14, 8.06 | <0.0001 | 0 |
| Headache | 3 | 618/584 | 1.24 | 0.82, 1.87 | 0.31 | 0 |
| Upper respiratory tract infection | 2 | 580/528 | 1.28 | 0.65, 2.52 | 0.48 | 0 |
| Back pain | 2 | 352/375 | 0.68 | 0.28, 1.63 | 0.39 | – |
| Urinary tract infection | 2 | 580/528 | 0.73 | 0.27, 1.96 | 0.53 | 0 |
| Nightmare | 2 | 352/375 | 4.16 | 0.69, 25.20 | 0.12 | 0 |
| Abnormal dreams | 2 | 352/375 | 1.39 | 0.51, 3.78 | 0.52 | 0 |
| Dizziness | 2 | 304/365 | 0.59 | 0.13, 2.60 | 0.49 | – |
Treatment discontinuation and individual adverse events for lemborexant 5 vs. placebo.
95% CI, 95% confidence interval; N, number of comparisons/studies; RR, risk ratio; TEAE, treatment-emergent adverse event. A TEAE was defined as an adverse event with onset date on or after the first dose of study drug up to 14 days after the last dose of study drug. Participants with two or more TEAEs with the same preferred term are counted only once for that preferred term.
Table 8 shows treatment discontinuation and individual adverse events for lemborexant 10 compared with placebo. There were only significant differences between two groups (lemborexant 10 and placebo) for any treatment-related TEAE, somnolence, and nightmare.
TABLE 8
| Adverse events | N | No. of cases (lemborexant 10/placebo) | RR | 95% CI | P-value | I2, % |
| Discontinuation due to all cause | 2 | 591/534 | 1.30 | 0.98, 1.71 | 0.07 | 54 |
| Discontinuation due to intolerability | 2 | 591/534 | 1.83 | 0.86, 3.87 | 0.12 | 0 |
| Any TEAE | 3 | 614/584 | 1.15 | 0.87, 1.53 | 0.33 | 0.69 |
| Any treatment-related TEAE | 3 | 614/584 | 2.08 | 1.61, 2.70 | <0.00001 | 0 |
| Any severe TEAE | 2 | 582/528 | 0.74 | 0.33, 1.66 | 0.46 | 0 |
| Any serious TEAE | 3 | 618/584 | 1.46 | 0.55, 3.90 | 0.45 | 0 |
| Any TEAE leading to discontinuation of study drug | 3 | 614/584 | 1.60 | 0.58, 4.39 | 0.36 | 0 |
| Any TEAE leading to interruption of study drug | 2 | 582/528 | 0.99 | 0.39, 2.50 | 0.97 | 0 |
| Death | 2 | 582/528 | Not estimable | – | – | – |
| Somnolence | 3 | 614/584 | 6.48 | 3.35, 12.56 | <0.00001 | 0 |
| Headache | 3 | 614/584 | 0.97 | 0.62, 1.50 | 0.88 | 0 |
| Upper respiratory tract infection | 2 | 582/528 | 0.65 | 0.11, 3.98 | 0.64 | 60 |
| Back pain | 2 | 346/375 | 1.32 | 0.55, 3.19 | 0.53 | 0 |
| Urinary tract infection | 2 | 582/528 | 1.84 | 0.82, 4.13 | 0.14 | 14 |
| Nightmare | 2 | 346/375 | 8.46 | 1.56, 45.78 | 0.01 | 0 |
| Abnormal dreams | 2 | 346/375 | 2.12 | 0.12, 35.91 | 0.60 | 70 |
| Dizziness | 2 | 241/324 | 0.64 | 0.12, 3.47 | 0.61 | – |
Treatment discontinuation and individual adverse events for lemborexant 10 vs. placebo.
95% CI, 95% confidence interval; N, number of comparisons/studies; RR, risk ratio; TEAE, treatment-emergent adverse event. A TEAE was defined as an adverse event with onset date on or after the first dose of study drug up to 14 days after the last dose of study drug. Participants with two or more TEAEs with the same preferred term are counted only once for that preferred term.
Treatment discontinuation and adverse events for lemborexant 5 and 10 therapies
Supplementary Table 2 shows treatment discontinuation and individual adverse events for lemborexant 5 compared to lemborexant 10. There were only significant differences in somnolence and urinary tract infection between two groups (lemborexant 5 and lemborexant 10) for any TEAE leading to discontinuation of study drug.
Discussion
The present study reports on meta-analysis of suvorexant or lemborexant compared with placebo for the treatment of insomnia patients. Overall, both medications were significantly more efficacious compared to placebo. Suvorexant was superior to placebo with regard to the primary efficacy outcomes (sTST, sTSO, sWASO, sQUAL, and sFRESH). Suvorexant was also superior to placebo regarding outcomes from rating scales and polysomnography, with the exceptions of weight at month 3. This study showed that there were significant differences between suvorexant and placebo in the most adverse events, with the exception of somnolence, excessive daytime sleepiness/sedation, fatigue, back pain, dry mouth, and abnormal dreams that their prevalence in suvorexant group was higher than placebo group. In addition, lemborexant 5 and 10 was superior to placebo with regard to the primary efficacy outcomes (sTST, sSE, and sWASO), with the exception of sWASO at month 1 for lemborexant 10, and also there was no significant difference between lemborexant 5 and 10 and placebo in the most adverse events, with the exception of somnolence for lemborexant 5 and 10 and nightmare for lemborexant 10 was higher than placebo group. Lemborexant 10 was superior to lemborexant 5 with regard to sSE that being less of somnolence and urinary tract infection in Lemborexant 10 confirms superiority of Lemborexant 10 compared to lemborexant 5.
In the evaluation of suvorexant, attention was paid to the side effects that could be based on the mechanism. Narcolepsy is associated with a decrease in orexin neurons and possibly an orexinergic tone (41–43), raising the theoretical likelihood that blocking the orexin receptors may mimic the signs or symptoms of narcolepsy, especially cataplexy (23). No events adjudicated as cataplexy were observed in the present meta-analysis. Surveillance has been associated with a small number of reports of sleep-related hallucinations and sleep paralysis, both of which can happen spontaneously in the general population (44, 45). In the present meta-analysis, there was no significant difference between suvorexant and placebo regarding hypnagogic/hypnopompic hallucination, sleep paralysis, and sleep-onset paralysis. Although orexin has been hypothesized to regulate weight (46), no difference with placebo in weight change was observed in the present meta-analysis.
The US Food and Drug Administration (FDA) has stated that their overall approach to insomnia medications is to use the lowest effective dose of suvorexant (47). Although one trial and the present meta-analysis based on the results of diary measures showed the 30 or 40 mg dose of suvorexant to be generally suitable and well-tolerated in insomnia patients, but the FDA concluded that the safety and tolerability data across the development programs, including results from driving studies in healthy participants, did not support the use of the 30 or 40 mg dose for the treatment of insomnia (36). Therefore, the FDA suggested that the totality of the clinical data supported the use of lower suvorexant doses of 10–20 mg (47). However, in the next trials, it is necessary to focus on the role of drug dosage in insomnia patients more carefully and better.
Studies have shown that treatment with lemborexant may alleviate some of the changes in sleep architecture seen in older people with insomnia (28, 35). In particular, the increase in TST and stage R sleep with lemborexant therapy illustrated in polysomnography recordings was consistent with the self-reported improvement in sleep retention associated with lemborexant in comparison with placebo. The present meta-analysis confirmed these results. Increased rates of somnolence showed evidence of dose-response in the lemborexant groups compared with placebo and increased rates of somnolence and urinary tract infection in lemborexant 10 compared with lemborexant 5 showed evidence of dose-response in the treatment of insomnia patients. However, sSE levels in lemborexant 10 was higher than lemborexant 5. Therefore, the researchers should consider the dose-response of lemborexant in the future trials more cautious.
Our analysis has a number of strengths: data from randomized, double-blind, placebo-controlled trials, and the number of patients evaluated were relatively large. In contrast, several limitations should be acknowledged. First, studies in this analysis included different drug dosing regimens. Second, some studies included few cases and may not have included statistical comparisons between the groups. Third, the number of studies included is limited, outcome measures and time points for heterogeneous analysis, and for some outcome measures, only a few studies have been reported.
Conclusion
The study showed that suvorexant and lemborexant are two efficacious and safe treatments for insomnia. As many patients with insomnia have significant comorbid conditions, further data in patients with insomnia and comorbid conditions are needed.
A brief summary
Current knowledge
Insomnia is a prevalent sleep disorder with various consequences. Pharmacotherapy and cognitive behavioral therapy for insomnia are main management strategies available. Dual orexin receptor antagonists are a new line of pharmacotherapeutic agents for management of insomnia. As DORA is a new line of therapy, practitioners may not be familiar with efficacy and side effects of these medications.
Study impact
Our meta-analysis indicated that DORAs are efficacious and safe. Better awareness of the efficacy and safety of this new mechanistic line of insomnia treatment may help practitioners to better manage their patients. As majority of clinical trials exclude patients with significant comorbid conditions, further studies needed to evaluate safety and efficacy in patients with insomnia and various comorbid conditions.
Statements
Data availability statement
The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.
Author contributions
HK: supervision of all steps, study design, and manuscript writing. MS: databases search, data analysis, and manuscript writing. SK: manuscript writing and editing and data analysis. MH: supervision of all steps, editing the manuscript, and scientific writing. AS: first idea, supervision, and manuscript writing and editing. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1070522/full#supplementary-material
Abbreviations
DORA, dual orexin receptor antagonists; PRISMA, preferred reporting items for systematic reviews and meta-analyses; FRESH, subjective refreshed feeling on waking (0–4 scale); sNAW, subjective number of awakenings; sQUAL, subjective quality of sleep (1–4 scale); sTSO, subjective time to sleep onset (minutes); sTST, subjective total sleep time (minutes); sWASO, subjective wake after sleep onset (minutes); sSOL, subjective sleep onset latency (minutes); sSE, subjective sleep efficiency (percentage); WMD, weighted mean difference; CGI-I, clinical global impression-improvement scale (1–7 scale); CGI-S, clinical global impression-severity scale (1–7 scale); ISI, insomnia severity index (0–28 scale); TST, total sleep time (minutes); LPS, latency to onset of persistent sleep (minutes); PGI-I, patient global impression-improvement scale (1–7 scale); PGI-S, patient global impression-severity scale (0–5 scale); WASO, wakefulness after persistent sleep onset (minutes); TEAE, treatment-emergent adverse event.
References
1.
RothT. Insomnia: definition, prevalence, etiology, and consequences.J Clin Sleep Med. (2007) 3(Suppl. 5):S7–10. 10.5664/jcsm.26929
2.
HertensteinEFeigeBGmeinerTKienzlerCSpiegelhalderKJohannAet alInsomnia as a predictor of mental disorders: a systematic review and meta-analysis.Sleep Med Rev. (2019) 43:96–105. 10.1016/j.smrv.2018.10.006
3.
MasonEHarveyA. Insomnia before and after treatment for anxiety and depression.J Affect Disord. (2014) 168:415–21. 10.1016/j.jad.2014.07.020
4.
ØyaneNMPallesenSMoenBEAkerstedtTBjorvatnB. Associations between night work and anxiety, depression, insomnia, sleepiness and fatigue in a sample of Norwegian nurses.PLoS One. (2013) 8:e70228. 10.1371/journal.pone.0070228
5.
ZengLZongQYangYZhangLXiangYNgCHet alGender difference in the prevalence of insomnia: a meta-analysis of observational studies.Front Psychiatry. (2020) 11:577429. 10.3389/fpsyt.2020.577429
6.
BuysseDJAngstJGammaAAjdacicVEichDRösslerW. Prevalence, course, and comorbidity of insomnia and depression in young adults.Sleep. (2008) 31:473–80. 10.1093/sleep/31.4.473
7.
TaylorDJMalloryLJLichsteinKLDurrenceHHRiedelBWBushAJ. Comorbidity of chronic insomnia with medical problems.Sleep. (2007) 30:213–8. 10.1093/sleep/30.2.213
8.
MunroA. The essential companion to the diagnostic and statistical manual of mental disorders: DSM-IV guidebook.J Psychiatry Neurosci. (1996) 21:210.
9.
ZhengWLuoXLiHKeXDaiQZhangCet alPrevalence of insomnia symptoms and their associated factors in patients treated in outpatient clinics of four general hospitals in Guangzhou, China.BMC Psychiatry. (2018) 18:232. 10.1186/s12888-018-1808-6
10.
Schutte-RodinSBrochLBuysseDDorseyCSateiaM. Clinical guideline for the evaluation and management of chronic insomnia in adults.J Clin Sleep Med. (2008) 4:487–504. 10.5664/jcsm.27286
11.
American Psychiatric Association.Diagnostic and Statistical Manuel of Mental Disorders.Washington, DC: American Psychiatric Association (1994).
12.
FirstMBReedGMHymanSESaxenaS. The development of the ICD-11 clinical descriptions and diagnostic guidelines for mental and behavioural disorders.World Psychiatry. (2015) 14:82–90. 10.1002/wps.20189
13.
World Health Organization.The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines.Geneva: World Health Organization (1992).
14.
SateiaM. International classification of sleep disorders.Chest. (2014) 146:1387–94. 10.1378/chest.14-0970
15.
SateiaMJBuysseDJKrystalADNeubauerDNHealdJL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline.J Clin Sleep Med. (2017) 13:307–49. 10.5664/jcsm.6470
16.
EquihuaADe La Herrán-AritaADrucker-ColinR. Orexin receptor antagonists as therapeutic agents for insomnia.Front Pharmacol. (2013) 4:163. 10.3389/fphar.2013.00163
17.
DubeyAHanduSMedirattaP. Suvorexant: the first orexin receptor antagonist to treat insomnia.J Pharmacol Pharmacother. (2015) 6:118. 10.4103/0976-500X.155496
18.
CoxCBreslinMWhitmanDSchreierJDMcGaugheyGBBoguskyMJet alDiscovery of the dual orexin receptor antagonist [(7 R)-4-(5-chloro-1, 3-benzoxazol-2-yl)-7-methyl-1, 4-diazepan-1-yl][5-methyl-2-(2 H-1, 2, 3-triazol-2-yl) phenyl] methanone (MK-4305) for the treatment of insomnia.J Med Chem. (2010) 53:5320–32. 10.1021/jm100541c
19.
WinrowCJGotterALCoxCDDoranSMTannenbaumPLBreslinMJet alPromotion of sleep by suvorexant–a novel dual orexin receptor antagonist.J Neurogenet. (2011) 25:52–61. 10.3109/01677063.2011.566953
20.
BeuckmannCTSuzukiMUenoTNagaokaKAraiTHigashiyamaH. In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist.J Pharmacol Exp Ther. (2017) 362:287–95. 10.1124/jpet.117.241422
21.
KishiTNomuraIMatsudaYSakumaKOkuyaMIkutaTet alLemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis.J Psychiatr Res. (2020) 128:68–74. 10.1016/j.jpsychires.2020.05.025
22.
HerringWJConnorKMSnyderESnavelyDBMorinCMLinesCet alEffects of suvorexant on the insomnia severity index in patients with insomnia: analysis of pooled phase 3 data.Sleep Med. (2019) 56:219–23. 10.1016/j.sleep.2018.09.010
23.
HerringWJConnorKMSnyderESnavelyDBZhangYHutzelmannJet alSuvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials.J Clin Sleep Med. (2016) 12:1215–25. 10.5664/jcsm.6116
24.
HerringWJConnorKMSnyderESnavelyDBZhangYHutzelmannJet alSuvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials.Am J Geriatr Psychiatry. (2017) 25:791–802. 10.1016/j.jagp.2017.03.004
25.
KishiTMatsunagaSIwataN. Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials.PLoS One. (2015) 10:e0136910. 10.1371/journal.pone.0136910
26.
KuriyamaATabataH. Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis.Sleep Med Rev. (2017) 35:1–7. 10.1016/j.smrv.2016.09.004
27.
McElroyHO’LearyBAdenaMCampbellRMonfaredAATMeierG. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.J Manag Care Spec Pharm. (2021) 27:1296–308. 10.18553/jmcp.2021.21011
28.
MolineMZammitGYardleyJPinnerKKumarDPerdomoCet alLack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.Postgrad Med. (2021) 133:71–81. 10.1080/00325481.2020.1823724
29.
MoherDLiberatiATetzlaffJAltmanDGPrisma Group.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.Int J Surg. (2010) 8:336–41. 10.1016/j.ijsu.2010.02.007
30.
DerSimonianRLairdN. Meta-analysis in clinical trials revisited.Contemp Clin Trials. (2015) 45:139–45. 10.1016/j.cct.2015.09.002
31.
MantelNHaenszelW. Statistical aspects of the analysis of data from retrospective studies of disease.J Natl Cancer Inst. (1959) 22:719–48.
32.
FanBKangJHeYHaoMDuWMaS. Efficacy and safety of suvorexant for the treatment of primary insomnia among Chinese: a 6-month randomized double-blind controlled study.Neurology Asia. (2017) 22:461–71.
33.
HerringWJCeesayPSnyderEBliwiseDBuddKHutzelmannJet alPolysomnographic assessment of suvorexant in patients with probable Alzheimer’s disease dementia and insomnia: a randomized trial.Alzheimers Dement. (2020) 16:541–51. 10.1002/alz.12035
34.
HerringWJSnyderEBuddKHutzelmannJSnavelyDLiuKet alOrexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.Neurology. (2012) 79:2265–74. 10.1212/WNL.0b013e31827688ee
35.
KärppMYardleyJPinnerKFilippovGZammitGMolineMet alLong-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.Sleep. (2020) 43:zsaa123. 10.1093/sleep/zsaa123
36.
MichelsonDSnyderEParadisEChengan-LiuMSnavelyDBHutzelmannJet alSafety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.Lancet Neurol. (2014) 13:461–71. 10.1016/S1474-4422(14)70053-5
37.
MurphyPMolineMMaylebenDRosenbergRZammitGPinnerKet alLemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study.J Clin Sleep Med. (2017) 13:1289–99. 10.5664/jcsm.6800
38.
RosenbergRMurphyPZammitGMaylebenDKumarDDhaddaSet alComparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial.JAMA Netw Open. (2019) 2:e1918254. 10.1001/jamanetworkopen.2019.18254
39.
HerringWJConnorKMIvgy-MayNSnyderELiuKSnavelyDBet alSuvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials.Biol Psychiatry. (2016) 79:136–48. 10.1016/j.biopsych.2014.10.003
40.
YangMMorinCMSchaeferKWallensteinGV. Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference.Curr Med Res Opin. (2009) 25:2487–94. 10.1185/03007990903167415
41.
BlackSWMorairtySRFisherSPChenTWarrierDRKilduffTS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.Sleep. (2013) 36:325–36. 10.5665/sleep.2442
42.
NishinoSRipleyBOvereemSLammersGJMignotE. Hypocretin (orexin) deficiency in human narcolepsy.Lancet. (2000) 355:39–40. 10.1016/S0140-6736(99)05582-8
43.
PeyronCFaracoJRogersWRipleyBOvereemSCharnayYet alA mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.Nat Med. (2000) 6:991–7. 10.1038/79690
44.
OhayonM. Prevalence of hallucinations and their pathological associations in the general population.Psychiatry Res. (2000) 97:153–64. 10.1016/S0165-1781(00)00227-4
45.
OhayonMMZulleyJGuilleminaultCSmirneS. Prevalence and pathologic associations of sleep paralysis in the general population.Neurology. (1999) 52:1194–1194. 10.1212/WNL.52.6.1194
46.
LeceaL dKilduffTSPeyronCGaoXFoyePEDanielsonPEet alThe hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.Proc Natl Acad Sci USA. (1998) 95:322–7. 10.1073/pnas.95.1.322
47.
FarkasR.Suvorexant Safety and Efficacy.Silver Spring, MD: US Food and Drug Administration (2013).
Summary
Keywords
insomnia, orexin receptor antagonist, suvorexant, lemborexant, randomized trial, meta-analysis
Citation
Khazaie H, Sadeghi M, Khazaie S, Hirshkowitz M and Sharafkhaneh A (2022) Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant. Front. Psychiatry 13:1070522. doi: 10.3389/fpsyt.2022.1070522
Received
14 October 2022
Accepted
21 November 2022
Published
12 December 2022
Volume
13 - 2022
Edited by
Mohammadreza Shalbafan, Iran University of Medical Sciences, Iran
Reviewed by
Takahiko Nagamine, Sunlight Brain Research Center, Japan; David Neubauer, School of Medicine, Johns Hopkins Medicine, United States
Updates
Copyright
© 2022 Khazaie, Sadeghi, Khazaie, Hirshkowitz and Sharafkhaneh.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sepideh Khazaie, sepidehkhazaieee@gmail.comAmir Sharafkhaneh, amirs@bcm.edu
This article was submitted to Psychopharmacology, a section of the journal Frontiers in Psychiatry
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.